

Edgar Filing: CAPRIUS INC - Form 8-K

CAPRIUS INC  
Form 8-K  
October 15, 2003

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF  
THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED) - SEPTEMBER 30, 2003

CAPRIUS, INC.  
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

DELAWARE	0-11914	22-2457487
(STATE OR OTHER JURISDICTION OF INCORPORATION)	(COMMISSION FILE NUMBER)	(I.R.S. EMPLOYER IDENTIFICATION NO.)

ONE PARKER PLAZA, FORT LEE, NEW JERSEY 07024  
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)

REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE - (201) 592-8838

ITEM 2. ACQUISITION OR DISPOSITION OF ASSETS

On October 9, 2003, Caprius, Inc., a Delaware corporation ("Registrant"), completed the closing of the sale of Strax Institute, Inc. (the "Strax Business"), its comprehensive breast imaging business, to Eastern Medical Technologies, Inc., a Delaware corporation ("EMT"), pursuant to a Stock Purchase Agreement dated September 30, 2003 (the "Purchase Agreement") among Registrant, EMT and the other parties thereto. The sale was effective as of September 30, 2003. The purchase price was \$400,000, subject to adjustment based upon the amount of the accounts payable and accounts receivable as of the date of closing. 50% of the purchase price, which had been held in escrow, was paid on closing and the balance is payable in installments commencing January 1, 2004 and ending December 31, 2004, evidenced by a note secured by the accounts receivables of Strax Institute, Inc. In addition, Registrant is

## Edgar Filing: CAPRIUS INC - Form 8-K

required to provided certain specified transitional services for up to 180 days pursuant to a Management Services Agreement. For further information regarding the transaction, see the Stock Purchase Agreement, the Non-negotiable Promissory Note and the Management Services Agreement which are filed as exhibits to this report and are incorporated herein by reference.

The Strax Business was a multi-modality breast care center performing approximately 20,000 procedures annually comprising of x-ray mammography, ultrasound, stereotactic biopsy and bone densitometry.

In addition, included as part of the Stock Purchase Agreement, Registrant and two of its executive officers are restricted for a period of five years from competing in the mammography and bone densitometry business in the States of Florida and New Jersey.

As part of the Strax transaction, the Registrant and George Aaron settled and terminated the pending BDC Corp. litigation, as disclosed in Registrant's Form 10-QSB for the quarterly period ended June 30, 2003 (refer to Part II, Item 1 for full explanation). The purchaser of Strax is an entity controlled by the same person who is a principal in BDC. The amounts payable in settlement of this litigation are to be offset against the purchase price under the Purchase Agreement. For further information see the Settlement Letter which is filed as an exhibit to the report and is incorporated herein by reference.

### Item 7. Financial Statements and Exhibits

The following financial statements and exhibits are filed herewith:

- a. Financial Statements of business acquired (not applicable).
- b. Pro forma financial information for the Registrant.

The following unaudited pro forma condensed consolidated financial statements are filed with this report:

Pro forma Condensed Consolidated Balance Sheet  
at June 30, 2003 F-1

Pro forma Condensed Consolidated Statements of Operations.

2

Year Ended September 30, 2002 F-2  
Nine Months Ended June 30, 2003 F-3

The pro forma condensed consolidated balance sheet of Registrant as of June 30, 2003 reflects the financial position of Registrant after giving effect to the disposition of the assets and assumption of the liabilities discussed in Item 2 and assumes the disposition took place on June 30, 2003. The pro forma condensed consolidated statements of operations for the fiscal year ended September 30, 2002, and the nine months ended June 30, 2003, assume that the disposition occurred on September 30, 2001, and are based on the operations of Registrant for the year ended September 30, 2002 and the nine months ended June 30, 2003.

## Edgar Filing: CAPRIUS INC - Form 8-K

The unaudited pro forma condensed consolidated financial statements have been prepared by Registrant based upon assumptions deemed proper by it. The unaudited pro forma condensed consolidated financial statements are not necessarily indicative of the future financial position or results of operations or actual results that would have occurred had the transaction been in effect as of the dates presented.

The unaudited pro forma condensed consolidated financial statements should be read in conjunction with Registrant's historical financial statements and related notes.

### c. Exhibits

- 10.1 Stock Purchase Agreement, among Registrant, Strax Institute Inc. and Eastern Medical Technologies, Inc. ("EMT"), dated as of September 30, 2003.
- 10.2 Non-negotiable Promissory Note of EMT to Registrant, dated September 30, 2003.
- 10.3 Security Agreement among EMT, Strax Institute, Inc., and Registrant, dated as of September 30, 2003.
- 10.4 Management Services Agreement between Registrant and Strax Institute Inc., dated as of September 30, 2003.
- 10.5 Settlement Letter among BDC Corp. d/b/a BDC Consulting Corp., Registrant and George Aaron, dated as of September 30, 2003.
- 99.1 Press Release, dated October 9, 2003.

3

### SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CAPRIUS, INC.

By: /s/ George Aaron  
-----  
Name: George Aaron  
Title: President

Dated: October 15, 2003

4

# Edgar Filing: CAPRIUS INC - Form 8-K

At June 30, 2003

PRO FORMA FINANCIAL INFORMATION  
CAPRIUS, INC. AND SUBSIDIARIES  
PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEETS  
AT JUNE 30, 2003  
(UNAUDITED)

	Historical	Pro Forma Adjustment Strax (a)	Other
ASSETS			
CURRENT ASSETS:			
Cash and cash equivalents (including \$303,660 of restricted funds held in escrow at June 30, 2003)	\$ 1,660,502	\$ 32,894	\$
Accounts receivable, net of reserve for bad debts of \$19,000 at June 30, 2003	397,624	228,335	
Inventories	532,300	-	
Note receivable short term	-	-	
Other current assets	122,745	19,612	
Total current assets	2,713,171	280,841	
PROPERTY AND EQUIPMENT:			
Medical equipment	314,318	314,318	
Office furniture and equipment	517,641	196,594	
Leasehold improvements	18,373	950	
	850,332	511,862	
Less: accumulated depreciation	634,598	480,761	
Net property and equipment	215,734	31,101	
OTHER ASSETS:			
Note receivable long term	-	-	
Deferred financing costs	18,340	-	
Goodwill, net of accumulated amortization	737,010	-	
Other intangibles, net of accumulated amortization	960,000	-	
Other	322,794	-	
Total other assets	2,038,144	-	
TOTAL ASSETS	\$ 4,967,049	\$ 311,942	\$
LIABILITIES AND STOCKHOLDERS' EQUITY			
CURRENT LIABILITIES:			
Accounts payable	\$ 1,258,335	\$ 62,522	
Accrued expenses	696,988	-	
Accrued compensation	201,947	57,608	
Current maturities of long-term debt and capital lease obligations	15,156	15,156	

# Edgar Filing: CAPRIUS INC - Form 8-K

Total current liabilities	2,172,426	135,286	
LONG-TERM DEBT AND CAPITAL LEASE OBLIGATIONS, net of current maturities	19,269	19,269	
TOTAL LIABILITIES	2,191,695	154,555	
MINORITY INTEREST IN MCM	116,435	-	
COMMITMENTS AND CONTINGENCIES	-	-	
STOCKHOLDERS' EQUITY:			
Preferred stock, \$.01 par value			
Authorized - 1,000,000 shares			
Issued and outstanding - Series A, none;			
Series B, convertible, 27,000 shares			
at June 30, 2003			
Liquidation preference \$2,700,000	2,700,000	-	
Common stock, \$.01 par value			
Authorized - 50,000,000 shares			
Issued - 20,419,062 shares at June 30, 2003	204,191	-	
Additional paid-in capital	67,579,258	-	
Accumulated deficit	(67,822,280)	157,387	
Treasury stock (22,500 common shares, at cost)	(2,250)	-	
Total stockholders' equity	2,658,919	157,387	
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$ 4,967,049	\$ 311,942	\$

F-1

## PRO FORMA FINANCIAL INFORMATION CAPRIUS, INC. AND SUBSIDIARIES PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS FOR THE YEAR ENDED SEPTEMBER 30, 2002 (Unaudited)

	Historical	Pro Forma Adjustment Strax (a)	Oth
REVENUES:			
Net patient service revenues	\$ 1,549,794	\$ 1,549,794	\$
Total revenues	1,549,794	1,549,794	
OPERATING EXPENSES:			

# Edgar Filing: CAPRIUS INC - Form 8-K

Cost of operations	1,169,491	1,169,491	
Selling, general and administrative	498,030	498,030	1,5
Goodwill impairment	67,356	67,356	
Provision for bad debt and collection costs	66,638	66,638	
	-----	-----	-----
Total operating expenses	1,801,515	1,801,515	1,5
	-----	-----	-----
Operating loss	(251,721)	(251,721)	(1,5
Interest expense	(10,619)	(10,619)	
	-----	-----	-----
Loss from continuing operations	\$ (262,340)	\$ (262,340)	\$ (1,5
	=====	=====	=====
Net loss per basic and diluted common share:			
Continuing operations	\$ (0.02)	\$ -	\$
	=====	=====	=====
Weighted average number of common shares outstanding, basic and diluted	17,171,140	-	
	=====	=====	=====

F-2

## PRO FORMA FINANCIAL INFORMATION CAPRIUS, INC. AND SUBSIDIARIES PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS FOR THE NINE MONTHS ENDED JUNE 30, 2003 (Unaudited)

	Historical	Pro Forma Ad Strax (a)	
	-----	-----	-----
REVENUES:			
Net patient service revenues	\$ 1,162,896	\$ 1,162,896	
Product sales and rental revenues	440,018	-	
Consulting income	37,500	-	
	-----	-----	-----
Total revenues	1,640,414	1,162,896	
	-----	-----	-----
OPERATING EXPENSES:			
Cost of patient service revenues	643,200	643,200	
Cost of product sales and rental revenue	381,645	-	
Research and development	135,051	-	
Selling, general and administrative	3,856,429	559,941	
Provision for bad debt and collection costs	36,262	36,262	
	-----	-----	-----

# Edgar Filing: CAPRIUS INC - Form 8-K

Total operating expenses	5,052,587	1,239,403
Operating loss	(3,412,173)	(76,507)
Interest expense	(7,353)	(5,439)
Loss from continuing operations	\$ (3,419,526)	\$ (81,946)
Net loss per basic and diluted common share		
Continuing operations	\$ (0.17)	\$ -
Weighted average number of common shares outstanding, basic and diluted	20,396,562	-

F-3